Código QR

Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial

Abstract Background Approximately 30-50% of patients with HER-2 + breast cancer develop brain metastases (BM). Stereotactic radiosurgery (SRS) is frequently used for local disease control. Tucatinib, an oral HER-2-selective tyrosine kinase inhibitor, has been demonstrated to be safe and efficacious...

Descrición completa

Gardado en:
Principais autores: Zouina Sarfraz, Ahmad Ozair, Mainak Bardhan, Amy K. Starosciak, Dilanis C. Perche, Lydia C. Hodgson, Yazmin Odia, Minesh P. Mehta, Rupesh Kotecha, Michael W. McDermott, Arun Maharaj, Ana Cristina Sandoval Leon, Reshma Mahtani, Manmeet S. Ahluwalia
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2025-12-01
Series:BMC Cancer
Assuntos:
Hormone receptor
Tyrosine kinase inhibitor
Targeted therapy
Precision medicine
Stereotactic radiotherapy
Metastatic breast cancer
Acceso en liña:https://doi.org/10.1186/s12885-025-15224-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares